InMode Ltd. (NASDAQ:INMD) Shares Purchased by Systematic Financial Management LP

Systematic Financial Management LP boosted its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 13.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 982,111 shares of the healthcare company’s stock after acquiring an additional 115,492 shares during the period. Systematic Financial Management LP owned about 1.17% of InMode worth $16,647,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Carmel Capital Partners LLC grew its stake in InMode by 6.9% during the third quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company’s stock worth $195,000 after buying an additional 741 shares during the period. Meritage Portfolio Management grew its stake in InMode by 9.5% during the third quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company’s stock worth $250,000 after buying an additional 1,284 shares during the period. Cetera Advisors LLC grew its stake in InMode by 8.9% during the first quarter. Cetera Advisors LLC now owns 17,028 shares of the healthcare company’s stock worth $368,000 after buying an additional 1,394 shares during the period. Inspire Advisors LLC grew its stake in InMode by 9.0% during the second quarter. Inspire Advisors LLC now owns 21,433 shares of the healthcare company’s stock worth $391,000 after buying an additional 1,778 shares during the period. Finally, Asset Dedication LLC purchased a new stake in InMode during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Trading Up 1.5 %

Shares of NASDAQ:INMD opened at $19.40 on Thursday. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80. The business has a 50-day moving average price of $17.77 and a two-hundred day moving average price of $17.52. The stock has a market capitalization of $1.63 billion, a P/E ratio of 10.49 and a beta of 2.07.

Wall Street Analyst Weigh In

Several research firms have recently commented on INMD. BTIG Research began coverage on shares of InMode in a research report on Thursday, October 17th. They set a “buy” rating and a $25.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research report on Thursday, October 31st. Finally, Barclays decreased their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Monday, October 14th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $22.60.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.